Response to atomoxetine in boys with high‐functioning autism spectrum disorders and attention deficit/hyperactivity disorder
- 6 April 2011
- journal article
- research article
- Published by Wiley in Acta Paediatrica
- Vol. 100 (9) , 1258-1261
Abstract
Aim: To study the efficacy and tolerability of atomoxetine in high‐functioning boys with autism spectrum disorders (ASD) and comorbid attention deficit/hyperactivity disorder (AD/HD).Methods: Fourteen boys (age 7–17) participated in a 10‐week open‐label study. Atomoxetine doses were 0.5 mg/kg/day in week 1 and 1.2–1.4 mg/kg/day in weeks 2–10. Changes in AD/HD symptoms were measured by the AD/HD Rating Scale, and global improvements by the Clinical Global Improvement Scale. Both measures were used to assess drug response. Assessments were done at baseline and at weeks 2, 4, 6 and 10. Teacher ratings were done at baseline and 10 weeks.Results: There were significant reductions in AD/HD symptoms rated by parents (p < 0.005) and by teachers (p < 0.05). One participant was rated as ‘Much improved’, five as ‘Moderately improved’, seven as ‘Minimally improved’, and one as ‘Unchanged or worse’. Seven subjects were classified as clinical responders. The most common adverse events were nausea and headache. Two participants discontinued treatment.Conclusion: Seven out of 14 boys with high‐functioning ASD and comorbid AD/HD showed significant reductions in AD/HD symptoms and were classified as responders to atomoxetine. Most children tolerated the drug well.Keywords
This publication has 14 references indexed in Scilit:
- Comorbid Psychiatric Disorders Associated with Asperger Syndrome/High-functioning Autism: A Community- and Clinic-based StudyJournal of Autism and Developmental Disorders, 2010
- Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum DisordersChild and Adolescent Psychiatric Clinics of North America, 2008
- Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacyChild and Adolescent Psychiatry and Mental Health, 2008
- Psychiatric Disorders in Children With Autism Spectrum Disorders: Prevalence, Comorbidity, and Associated Factors in a Population-Derived SampleJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential ResponseAmerican Journal of Psychiatry, 2008
- Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot StudyJournal of Child and Adolescent Psychopharmacology, 2006
- Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental DisordersJournal of Child and Adolescent Psychopharmacology, 2006
- ADHD rating scale IV: psychometric properties from a multinational study as clinician-administered instrumentInternational Journal of Methods in Psychiatric Research, 2005
- Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders With HyperactivityArchives of General Psychiatry, 2005
- Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental DisordersJournal of Child and Adolescent Psychopharmacology, 2005